Tag - EVLO

Markets

Cantor starts Evelo Biosciences at OW; PT $28

Cantor Fitzgerald launched coverage of Evelo Biosciences (NASDAQ:EVLO) with an “overweight” rating and 12-month price target of $28. The stock closed at $16.08 on June 22. Evelo is developing oral therapies derived from...

June 23, 2021

Developments

Evelo doses first patient in Phase 2 psoriasis study

Evelo Biosciences (NASDAQ:EVLO) dosed the first patient in its Phase 2 study evaluating EDP1815 for the treatment of mild-to-moderate psoriasis. The placebo-controlled study will enroll 225 patients to evaluate three...

October 13, 2020

Tag - EVLO

Cantor starts Evelo Biosciences at OW; PT $28

Evelo doses first patient in Phase 2 psoriasis study

General

More